Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce substantial weight loss (10-25%) and improve glycemic control through appetite suppression and enhanced satiety.
GLP-1 and GIP/GLP-1 agonists are highly effective for weight loss, achieving 10-25% reduction. They work by suppressing appetite and increasing satiety. Treatment requires a gradual dose increase to manage common gastrointestinal side effects like nausea. These drugs are indicated for adults with obesity or overweight with comorbidities, and should be used alongside lifestyle changes.
Agents including liraglutide and semaglutide, plus the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide, induce substantial weight loss (approximately 10% to 25%) through appetite suppression and enhanced satiety while improving glycemic control.
Why this rating
Supported by multiple large-scale Phase 3 RCTs (SCALE, STEP, SURPASS, SURMOUNT) cited in the review.
Source
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Jang Won Son · Journal of Korean Medical Association · 2026
DOI 10.5124/jkma.25.0138
More from this paper
- GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.Strong
- Next-generation GLP-1 based therapies (oral formulations, small-molecule agonists, multi-receptor agonists) aim to achieve greater efficacy (>25% weight loss), improved tolerability, and novel delivery platforms.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →